Rita C. Peters

Congressional partisanship creates noise, but no funding for Zika virus research.

CPhI Pharma Awards seek nominations for excellence in development and manufacturing.

With technology advances, continuous manufacturing shows steady progress to more widespread adoption.

Pharma companies must weigh cost efficiencies of global API sourcing with increased complexities of monitoring for compliance and quality.

A global API marketplace increases the burden of supply chain monitoring for drug companies.

Thought leaders tackle drug shortages and manufacturing innovations.

Standardized testing protocols are crucial for acceptance of single-use systems.

Suppliers must develop new technologies to drive the bio/pharma innovation engine.

Mergers and acquisitions have changed the shape of the contract services market as big players seek to build full-service capabilities.

FDA approved 45 novel new drugs in 2015, the highest number of approvals since 1996 and second-highest ever.

Infrastructure and payer decisions will determine drug choices in emerging and developed regions.

Amid corporate restructurings, regulatory initiatives, and aging R&D assets, will drug development accelerate or stall in 2016?

FDA approved 45 novel new drugs in 2015, the highest number of approvals since 1996 and second-highest ever.

Regulatory, corporate restructuring, and manufacturing issues will challenge bio/pharma to meet the needs and expectations of patients around the world.

Employers have work to do to improve job satisfaction and retain qualified workers.

Bio/pharma employee dissatisfaction with pay and progress may direct some to new career pathways.

Intellectual challenge, job security, and opportunity for advancement contribute to employee happiness, but the ultimate prize may be a satisfactory salary for bio/pharma employees in Europe.

The CPhI Pharma Awards celebrate innovations in the pharma industry.

This special issue combines technical articles on leading pharma industry topics and a comprehensive preview of the upcoming CPhI Worldwide trade show

FDA notes progress in drug development, but cites scientific and funding roadblocks.

The bio/pharma industry enjoys success, but it cannot ignore patient access to medications.

Peer-reviewed papers and technical articles can help advance bio/pharmaceutical development.

Pharma can boast of big-picture successes, but needs to work on operational issues.

FDA approves a biosimilar and loses a commissioner in March.

Sessions address cell therapies, tableting, continuous processes, serialization, and more.

Biosimilars, supply chain security, quality metrics, and elemental impurities headline guidance topics on FDA’s 2015 agenda.

Initiatives to speed drug development must pass Congress and special interest groups.

New designations lead to faster drug approvals, but there is more work to be done.

Professionals share the ups and downs of working in the bio/pharma industry.

Ebola Virus Disease (EVD) is a severe, often fatal disease that is transmitted human-to-human through bodily fluids.